George P Patrinos
Overview
Explore the profile of George P Patrinos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
328
Citations
4699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fragoulakis V, Koufaki M, Mlinsek G, Blagus T, Klen J, Patrinos G, et al.
Pharmacogenomics J
. 2025 Mar;
25(1-2):6.
PMID: 40064851
Tacrolimus (TAC) is one of the most widely prescribed maintenance immunosuppressant drugs in solid organ transplantation. Kidney transplantation is often the preferred treatment for patients with the kidney failure and...
2.
Liakopoulou A, Letsiou S, Avgoustakis K, Patrinos G, Lamari F, Hatziantoniou S
Pharmaceutics
. 2025 Feb;
17(2).
PMID: 40006512
Oxidative stress significantly impacts skin health, contributing to conditions like aging, pigmentation, and inflammatory disorders. Curcumin, with its potent antioxidant properties, faces challenges of low solubility, stability, and bioavailability. This...
3.
Nikolopoulos T, Bochalis E, Chatzilygeroudi T, Chondrou V, Dereki I, Athanasopoulou K, et al.
Mol Med
. 2025 Feb;
31(1):59.
PMID: 39953389
Background: Patients with higher-risk (HR) myelodysplastic syndrome (MDS), ineligible for allogeneic hematopoietic stem cell transplantation (alloHSCT), require prompt therapeutic interventions, such as treatment with hypomethylating agents (HMAs) to restore normal...
4.
Patrinos G, Karamperis K, Koufaki M, Skokou M, Kordou Z, Sparaki E, et al.
Hum Genomics
. 2025 Feb;
19(1):11.
PMID: 39920803
Pharmacogenomics (PGx) aims to delineate a patient's genetic profile with differences in drug efficacy and/or toxicity, particularly focusing on genes encoding for drug-metabolizing enzymes and transporters. Clinical implementation of PGx...
5.
OConnell K, Koromina M, van der Veen T, Boltz T, David F, Yang J, et al.
Nature
. 2025 Jan;
PMID: 39843750
Bipolar disorder is a leading contributor to the global burden of disease. Despite high heritability (60-80%), the majority of the underlying genetic determinants remain unknown. We analysed data from participants...
6.
Sarhangi N, Fahimfar N, Rouhollah F, Sharifi F, Bidkhori M, Nikfar S, et al.
J Diabetes Metab Disord
. 2024 Nov;
23(2):2279-2287.
PMID: 39610552
Objectives: The efficacy and safety of drug treatments vary widely due to genetic variations. Pharmacogenomics investigates the impact of genetic variations on patient drug response. This research investigates the frequency...
7.
Hasanzad M, Patrinos G, Aghaei Meybodi H, Nikfar S, Larijani B
J Diabetes Metab Disord
. 2024 Nov;
23(2):2411-2414.
PMID: 39610506
No abstract available.
8.
Sarhangi N, Rouhollah F, Niknam N, Sharifi F, Nikfar S, Larijani B, et al.
Daru
. 2024 Oct;
32(2):715-727.
PMID: 39424756
Background: Cancer treatment has improved over the past decades, but many cancer patients still experience adverse drug reactions (ADRs). Pharmacogenomics (PGx), known as personalized treatment, is a pillar of precision...
9.
Karamperis K, Katz S, Melograna F, Ganau F, Van Steen K, Patrinos G, et al.
iScience
. 2024 Oct;
27(10):110916.
PMID: 39391720
Genetic ancestry plays a major role in pharmacogenomics, and a deeper understanding of the genetic diversity among individuals holds immerse promise for reshaping personalized medicine. In this pivotal study, we...
10.
Liu W, Li Y, Patrinos G, Xu S, Thong M, Chen Z, et al.
Cell Res
. 2024 Sep;
34(11):747-750.
PMID: 39261573
No abstract available.